in male rats. Comparison with the metabolic profile of NNEI to its indazole analogue MN-18 unveiled marked distinctions in pharmacokinetic parameters and metabolic pathways. In particular, compound 95 served as by far the most efficacious from the shortlisted compounds within an HCT116 tumor xenograft product, which also could inhibit The expans